Adaptive Biotechnologies Corporation Stock price

Equities

ADPT

US00650F1093

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:29:05 2024-03-01 pm EST 5-day change 1st Jan Change
4.195 USD +2.07% Intraday chart for Adaptive Biotechnologies Corporation +3.47% -14.69%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 170M Sales 2024 * 176M Capitalization 596M
Net income 2023 -225M Net income 2024 * -193M EV / Sales 2023 3.84 x
Net cash position 2023 55.68M Net cash position 2024 * 96.2M EV / Sales 2024 * 2.85 x
P/E ratio 2023
-3.14 x
P/E ratio 2024 *
-3.12 x
Employees 790
Yield 2023 *
-
Yield 2024 *
-
Free-Float 97.95%
More Fundamentals * Assessed data
Dynamic Chart
JPMorgan Adjusts Price Target on Adaptive Biotechnologies to $8 From $11, Maintains Overweight Rating MT
Adaptive Biotechnologies' Q4 Loss Widens; Revenue Declines; Shares Down MT
Transcript : Adaptive Biotechnologies Corporation, Q4 2023 Earnings Call, Feb 14, 2024
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q4 Revenue $45.8M, vs. Street Est of $48.5M MT
Adaptive Biotechnologies Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Transcript : Adaptive Biotechnologies Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 01:30 PM
Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting CI
Adaptive Biotechnologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Adaptive Biotechnologies Corporation, Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q3 Revenue $37.9M, vs. Street Est of $43M MT
Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023 CI
Adaptive Biotechnologies Partners With BeiGene on Minimal Residual Disease Testing of Potential Treatments for Lymphoid Malignancies MT
Adaptive Biotechnologies Corporation Announces New Translational Collaboration to Measure Minimal Residual Disease with Clonoseq(R) Assay Across Beigene's Lymphoid Malignancy Pipeline CI
Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating MT
BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating MT
More news

Latest transcript on Adaptive Biotechnologies Corporation

1 day-0.96%
1 week+5.93%
1 month+11.99%
3 months-6.16%
6 months-39.29%
Current year-16.12%
More quotes
1 week
3.96
Extreme 3.96
4.35
1 month
3.41
Extreme 3.41
4.35
Current year
3.41
Extreme 3.41
5.07
1 year
2.61
Extreme 2.605
9.17
3 years
2.61
Extreme 2.605
55.63
5 years
2.61
Extreme 2.605
71.25
10 years
2.61
Extreme 2.605
71.25
More quotes
Managers TitleAgeSince
Founder 51 09-09-07
Chief Executive Officer 49 09-09-07
President 52 11-03-31
Members of the board TitleAgeSince
Director/Board Member 61 13-01-31
Director/Board Member 53 21-03-16
Director/Board Member 68 13-12-31
More insiders
Date Price Change Volume
24-03-01 4.175 +1.58% 362 417
24-02-29 4.11 -0.96% 1,035,665
24-02-28 4.15 -2.81% 1,258,859
24-02-27 4.27 +2.64% 1,001,001
24-02-26 4.16 +2.97% 879,519

Delayed Quote Nasdaq, February 29, 2024 at 04:00 pm EST

More quotes
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine (IM) platform combines a suite of chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its clinical diagnostic product, clonoSEQ, is used for the detection and monitoring minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). The IM business consists of two areas: IM Pharma Services and Drug Discovery. Its immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.11 USD
Average target price
6.833 USD
Spread / Average Target
+66.26%
Consensus
  1. Stock
  2. Equities
  3. Stock Adaptive Biotechnologies Corporation - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW